Compare Agilent Technologies Inc (A) vs AbbVie Inc (ABBV) Price & Performance

Agilent Technologies (A) trades at $156.47, up 1.81% on the day, with a bullish technical outlook and strong institutional interest. Recent Q3 2026 earnings beat expectations with EPS of $1.62 versus $1.49 expected, and the company raised full-year guidance. Valuation ratios are elevated with a P/E of 30.84 and P/S of 6.01, reflecting premium pricing for its consistent profitability and market position in life sciences tools.

The stock offers upside to the consensus price target of $170, supported by solid fundamentals and positive analyst sentiment, but faces risks from high valuation multiples and potential market volatility. Revenue growth and margin expansion in recent quarters provide a foundation for continued performance, though investors should weigh these against macroeconomic pressures on research spending.

AbbVie (ABBV) trades at $264.00, up 0.54% on the day, with a bullish technical signal and strong analyst consensus. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.65 surpassing the $3.61 estimate. Revenue growth is robust, reaching $61.16 billion in 2025, driven by immunology drugs Skyrizi and Rinvoq offsetting Humira declines. The company maintains a high gross profit margin of 71.48% and offers a solid dividend, with recent payouts of $1.73 per share.

Outlook remains positive with a consensus price target of $287.08, implying ~9% upside. Key opportunities include pipeline strength in oncology and sustained immunology growth. Risks involve high debt levels, patent expirations in the 2030s, and regulatory pressures. The stock is well-positioned for growth but requires monitoring of execution on new drug launches and debt management.